Local view for "http://purl.org/linkedpolitics/eu/plenary/2010-09-21-Speech-2-517"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2010-09-21"^^xsd:date2
dcterms:Is Part Of	lp_eu:Pharmacovigilance of medicinal products (amendment of Regulation (EC) No 726/2004) - Pharmacovigilance (amendment of Directive 2001/83/EC) (debate)2
dcterms:Language	"it"^^xsd:language2
lpv:document identification number	"en.20100921.18.2-517"2
lpv:hasSubsequent	lp_eu:2010-09-21-Speech-2-5182
lpv:speaker	lp:Sergio Berlato2
lpv:spokenAs	member; EPP (2009-07-14--2014-06-30)3 unknown; Il Popolo della Libertà (2009-07-14--2013-12-08)3 member; ENVI (2009-07-16--2012-01-18)3 substitute; AFCO (2009-07-16--2012-01-18)3 substitute; Delegation to the EU-Russia Parliamentary Cooperation Committee (2009-09-16--2014-06-30)3 member; Delegation for relations with the United States (2009-09-16--2014-06-30)3
lpv:translated text	"Medicinal products make an essential contribution to the health of European Union citizens. They may, however, sometimes lead to severe side effects which, according to the Commission, are the cause of approximately 5% of hospital admissions and deaths. Over recent years, cases have been recorded of medicinal products that have given rise to far from negligible secondary effects on patients despite having been marketed following the required control procedure. This situation emphasises the need for the Union to avail itself of an effective pharmacovigilance policy with the aim of protecting the health of European citizens. I believe that an efficient pharmacovigilance system must allow the timely indication of medicinal product side effects to the competent authorities and, above all, when necessary, the swift withdrawal of hazardous drugs from the market. I also support the proposals contained in the report under discussion that aim to improve cooperation between Member States over pharmacovigilance and strengthen the criteria for granting marketing authorisations to new medicinal products. Lastly, I call on the Commission to consider revising the composition of medicinal product package leaflets with the aim of also improving information on the use of a drug."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph